Menu

Dr. David Bartlett is the director of Multidisciplinary Disease Site Clinical and Research Programs for UPMC Hillman Cancer Center in Pennsylvania. In addition to working at the Cancer Center, Dr. Bartlett is the Bernard Fisher Professor of Surgery at the University of Pittsburgh School of Medicine, vice chairman for surgical oncology and gastrointestinal services and vice chairman of the David C. Koch Regional Perfusion Cancer Therapy Center on the UPMC campus.

He is board certified in general surgery and specializes in treating peritoneal mesothelioma and other carcinomas that develop in the peritoneal region, such as liver and bile duct cancer and abdominal sarcomas. A specific area of interest to Dr. Bartlett is the research and development of new treatment techniques for patients that have developed cancer in the peritoneal cavity. His expertise lies in delivering targeted chemotherapy agents directly to the blood vessels that are associated with a tumor. He has also assisted with developing a technique to deliver chemotherapy directly into the peritoneal cavity in patients that present with localized malignancies in that region.

Dr. Bartlett has conducted research at the National Cancer Institute to develop new surgical techniques that resulted in improved survival rates for patients with cancer of the abdomen and liver. In addition to his work in developing techniques to deliver targeted chemotherapy to tumor sites, he is also now investigating techniques to deliver gene therapy directly to tumors. He is the author of articles featured in peer reviewed journals, covering topics such as targeted regional treatment and gene therapies.

Main Speciality: Surgical Oncology, Gastrointestinal Services

Other Interests & Specialties: Surgery, surgical oncology, minimally invasive surgery, abdominal sarcomas, liver and bile duct cancers and gene therapy.

Certifications, Awards & Accolades: American Board of Surgery Certification in General Surgery, Lifetime Achievement Award, American Medical Association member, Society of Surgical Oncology member, Society of Laparoendoscopic Surgeons member, American Society of Gene Therapy member, Society of University Surgeons member, American Society of Clinical Oncology member, member of the American Association for Cancer Research, member of the Society of Laparoendoscopic Surgeons, member of the American Society of Peritoneal Surface Malignancies

Education & Experience:

  • Medical Degree from University of Houston at Clear Lake
  • Residency at Hospital of the University of Pennsylvania
  • Fellowship in Surgical Oncology at Memorial Sloan-Kettering Cancer Center

Publications:
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapyJournal of Clinical Oncology. December 2003;21(24):4560-7. doi: 10.1200/JCO.2003.04.150

Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesotheliomaThe Cancer Journal from Scientific American. May 1997;3(3):174-9.

Mesothelioma Clinical Trials by David Bartlett, MD

Dr. David Bartlett is associated with the following clinical trials:

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies


Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pancreatic Neoplasms, Neoplasms

Last Updated: April 11, 2019

Status: Completed

Photo of Dr. David Bartlett

Get Help Contacting Dr. David Bartlett


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe